Expression of vitamin D receptor (VDR), parathyroid hormone (PTH)/PTH-related peptide receptor type 1(PTHR1), calcium sensing receptor (CaSR) and fibroblast growth factor 23 (FGF-23) in bone tissue in hypercalciuric stone forming patients

• Grant number: 08/10515-0
• Support Opportunities: Regular Research Grants
• Duration: March 01, 2009 - August 31, 2011
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Ita Pfeferman Heilberg
• Grantee: Ita Pfeferman Heilberg
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil

Abstract

Idiopathic hypercalciuria is the most common metabolic abnormality in patients with nephrolithiasis, occurring in up to 50% of patients. The loss of bone mass among hypercalciuric patients, evidenced by a decreased bone mineral density is well established in the literature. Previous bone histomorphometric studies conducted in our Service demonstrated low bone formation, increased bone resorption, and a mineralization defect in such patients. In a previous study, in order to investigate the pathophysiological mechanisms underlying bone disease in hypercalciuria setting, we evaluated the role of cytokines at a bone level, through an immunohistochemical technique. We observed a higher bone expression of the receptor activator of NF-ºB ligand (RANKL) and osteoprotegerin (OPG) and a lower expression of transforming growth factor-beta (TGF-²). Considering the interaction between OPG/RANKL system with calciotropic hormones, and aimed at further elucidating the different aspects of bone involvement in idiopathic hypercalciuria, the purpose of the current project is to perform bone immunohistochemical techniques in the field of Renal Lithiasis in our University. The objective of the present study is to evaluate the bone expression of vitamin D receptor (VDR), parathyroid hormone (PTH)/PTH-related peptide receptor type 1 (PTHR1), calcium sensing receptor (CaSR) and fibroblast growth factor 23 (FGF-23) in hypercalciuric stone-forming patients. Immunohistochemical analysis will be performed in calcified bone fragments obtained from transiliac bone biopsies previously performed. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MENON, VIVIANE BARCELLOS; AFFONSO MOYSES, ROSA MARIA; GOMES, SAMIRAH ABREU; DE CARVALHO, ALUIZIO BARBOSA; JORGETTI, VANDA; HEILBERG, ITA PFEFERMAN. Expression of Fibroblast Growth Factor 23, Vitamin D Receptor, and Sclerostin in Bone Tissue from Hypercalciuric Stone Formers. Clinical Journal of the American Society of Nephrology, v. 9, n. 7, p. 1263-1270, JUL 7 2014. (08/10515-0)